Literature DB >> 4066726

Biocompatibility of Delrin 150: a creep-resistant polymer for total joint prostheses.

J S Fister, V A Memoli, J O Galante, W Rostoker, R M Urban.   

Abstract

A thermoplastic polymer, Delrin 150 (polyoxymethylene homopolymer), with creep resistance ten times that of ultrahigh-molecular-weight polyethylene, is used as a material for total joint prostheses. A study was made of the local and systemic host response to this polymer when implanted in three different mammalian species. 316 LC stainless steel was used as a control. The materials were implanted into muscle and bone as solid cylinders. A total of 446 samples were implanted into 74 animals. The duration of implantation ranged from 2 weeks to 2 years. A semi-quantitative evaluation of local tissue reaction was performed. For each implant, 16 histological criteria were graded for severity of host tissue reaction. The liver, spleen, kidneys, pancreas, and lungs from each animal were also studied for evidence of systemic toxicity. The polymer implants exhibited a mild tissue reaction with the same characteristics as the control. Local tumor formation, bone osteolysis, and surrounding muscle necrosis were not seen. No pathological changes compatible with systemic toxicity by Delrin 150 were observed in the study of the organs. Delrin 150 in solid form did not exhibit local or systemic toxicity and is therefore biocompatible by this study. Powder implantation studies should be performed to simulate tissue response to wear particles.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4066726     DOI: 10.1002/jbm.820190505

Source DB:  PubMed          Journal:  J Biomed Mater Res        ISSN: 0021-9304


  2 in total

1.  Bone formation in porous implants of delrin and commercially pure titanium.

Authors:  F Buch; T Albrektsson
Journal:  Arch Orthop Trauma Surg       Date:  1990       Impact factor: 3.067

2.  Three-dimensional paper-based model for cardiac ischemia.

Authors:  Bobak Mosadegh; Borna E Dabiri; Matthew R Lockett; Ratmir Derda; Patrick Campbell; Kevin Kit Parker; George M Whitesides
Journal:  Adv Healthc Mater       Date:  2014-02-12       Impact factor: 9.933

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.